GLP-1 receptor agonists, particularly Ozempic, have seen widespread use since their FDA approval for Type 2 diabetes and weight management. However, reports have emerged indicating potential psychiatric adverse events, including depression, anxiety, and suicidality, with nearly 500 cases logged by fall 2023. While the FDA databases cannot establish direct causation, social media discussions indicate a growing concern over mental health side effects in users. Ongoing research is crucial to determine the safety and psychological impact of these increasingly popular medications.
"In late 2017, the FDA approved the first GLP-1 receptor agonist, Ozempic, which initially was used for Type 2 diabetes, later gaining weight management approval in 2022."
"By the fall of 2023, nearly 500 reports of mental health side effects from GLP-1 drugs were filed; notable symptoms included anxiety, depression, and suicidal thoughts."
Collection
[
|
...
]